Giovanna Schiavoni

List of Publications by Citations

48 papers	4,520 citations	28 h-index	58 g-index
58 ext. papers	5,260 ext. citations	6.8 avg, IF	5.19 L-index

#	Paper	IF	Citations
48	Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. *Immunity*, **2001**, 14, 461-70	32.3	763
47	Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. *Cell Death and Differentiation*, **2014**, 21, 15-25	12.7	526
46	Type I interferons produced by dendritic cells promote their phenotypic and functional activation. *Blood*, **2002**, 99, 3263-71	2.2	380
45	IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. *Journal of Immunology*, **2001**, 167, 1179-87	5.3	343
44	ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. *Journal of Experimental Medicine*, **2002**, 196, 1415-25	16.6	338
43	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. *Science*, **2015**, 350, 972-8	33.3	267
42	Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. *Cancer Research*, **2011**, 71, 768-78	10.1	240
41	Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. *Blood*, **2000**, 95, 2024-2030	2.2	175
40	Eosinophils: The unsung heroes in cancer?. *OncoImmunology*, **2018**, 7, e1393134	7.2	104
39	The tumor microenvironment: a pitch for multiple players. *Frontiers in Oncology*, **2013**, 3, 90	5.3	102
38	Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. *Lab on A Chip*, **2013**, 13, 229-39	7.2	101
37	ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells. *Blood*, **2004**, 103, 2221-8	2.2	98
36	Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. *Journal of Immunology*, **2011**, 186, 5142-50	5.3	86
35	Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response. *Frontiers in Immunology*, **2013**, 4, 483	8.4	85
34	IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. *OncoImmunology*, **2017**, 6, e1317420	7.2	84
33	Type I IFN protects permissive macrophages from Legionella pneumophila infection through an IFN-gamma-independent pathway. *Journal of Immunology*, **2004**, 173, 1266-75	5.3	70
32	The dangerous liaison between pollens and pollution in respiratory allergy. *Annals of Allergy, Asthma and Immunology*, **2017**, 118, 269-275	3.2	56

31	Cancer-driven dynamics of immune cells in a microfluidic environment. *Scientific Reports*, **2014**, 4, 6639	4.9	55
30	Organs on chip approach: a tool to evaluate cancer -immune cells interactions. *Scientific Reports*, **2017**, 7, 12737	4.9	54
29	The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity. *Frontiers in Immunology*, **2018**, 9, 2601	8.4	44
28	IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. *Journal of Leukocyte Biology*, **2006**, 80, 1500-11	6.5	42
27	Combining Type I Interferons and 5-Aza-2SDeoxycitidine to Improve Anti-Tumor Response against Melanoma. *Journal of Investigative Dermatology*, **2017**, 137, 159-169	4.3	41
26	IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. *Neoplasia*, **2012**, 14, 1223-35	6.4	41
25	STAT1 regulates IFN-alpha beta- and IFN-gamma-dependent control of infection with Chlamydia pneumoniae by nonhemopoietic cells. *Journal of Immunology*, **2006**, 176, 6982-90	5.3	40
24	A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. *Journal of Immunotoxicology*, **2014**, 11, 337-46	3.1	38
23	Regulation of immune cell homeostasis by type I interferons. *Cytokine and Growth Factor Reviews*, **2010**, 21, 227-36	17.9	32
22	Type I IFN regulate DC turnover in vivo. *European Journal of Immunology*, **2009**, 39, 1807-18	6.1	30
21	ICSBP/IRF-8 differentially regulates antigen uptake during dendritic-cell development and affects antigen presentation to CD4+ T cells. *Blood*, **2006**, 108, 609-17	2.2	23
20	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. *Cancer Immunology Research*, **2018**, 6, 658-670	12.5	21
19	Novel allergic asthma model demonstrates ST2-dependent dendritic cell targeting by cypress pollen. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 686-695.e7	11.5	21
18	IL-33 Promotes CD11b/CD18-Mediated Adhesion of Eosinophils to Cancer Cells and Synapse-Polarized Degranulation Leading to Tumor Cell Killing. *Cancers*, **2019**, 11,	6.6	19
17	From Petri Dishes to Organ on Chip Platform: The Increasing Importance of Machine Learning and Image Analysis. *Frontiers in Pharmacology*, **2019**, 10, 100	5.6	18
16	Mycobacterium tuberculosis PstS1 amplifies IFN-□and induces IL-17/IL-22 responses by unrelated memory CD4+ T cells via dendritic cell activation. *European Journal of Immunology*, **2013**, 43, 2386-97	6.1	17
15	Basophils in Tumor Microenvironment and Surroundings. *Advances in Experimental Medicine and Biology*, **2020**, 1224, 21-34	3.6	14
14	Is There a Role for Basophils in Cancer?. *Frontiers in Immunology*, **2020**, 11, 2103	8.4	10

13	Oncoimmunology Meets Organs-on-Chip. *Frontiers in Molecular Biosciences*, **2021**, 8, 627454	5.6	9
12	Multi-scale generative adversarial network for improved evaluation of cell–cell interactions observed in organ-on-chip experiments. *Neural Computing and Applications*, **2021**, 33, 3671-3689	4.8	8
11	TIM-3 as a molecular switch for tumor escape from innate immunity. *Frontiers in Immunology*, **2012**, 3, 418	8.4	6
10	The dual role of IRF8 in cancer immunosurveillance. *OncoImmunology*, **2013**, 2, e25476	7.2	6
9	Interferon regulatory factor 8-deficiency determines massive neutrophil recruitment but T cell defect in fast growing granulomas during tuberculosis. *PLoS ONE*, **2013**, 8, e62751	3.7	6
8	Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight. *Frontiers in Immunology*, **2020**, 11, 571593	8.4	6
7	High-throughput analysis of cell-cell crosstalk in ad hoc designed microfluidic chips for oncoimmunology applications. *Methods in Enzymology*, **2020**, 632, 479-502	1.7	5
6	Eosinophils in the Tumor Microenvironment. *Advances in Experimental Medicine and Biology*, **2020**, 1273, 1-28	3.6	5
5	Accelerating the experimental responses on cell behaviors: a long-term prediction of cell trajectories using Social Generative Adversarial Network. *Scientific Reports*, **2020**, 10, 15635	4.9	4
4	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. *Cells*, **2020**, 9,	7.9	4
3	Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis. *Oncotarget*, **2016**, 7, 59754-59765	3.3	3
2	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring. *Journal of Immunology Research*, **2020**, 2020, 1938704	4.5	1
1	A Clonogenic Assay to Quantify Melanoma Micrometastases in Pulmonary Tissue. *Methods in Molecular Biology*, **2021**, 2265, 385-406	1.4	